Simultaneous determination of erlotinib and its major metabolites in human plasma using an isocratic liquid chromatography tandem mass spectrometry

• In: Posters G - Pharmacokinetics (PK), Pharmacodynamics (PD) and Systems Pharmacology
• At: PSWC, Melbourne (Australia) (2014)
• Type: Poster
• Poster code: PG-017
• By: ISHIDA, Takuya (Hamamatsu University School of Medicine, Hospital Pharmacy, Hamamatsu, Japan)
• Co-author(s): Naito, Takafumi (Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Suda, Takafumi (Hamamatsu University School of Medicine, Hamamatsu, Japan)
  Kawakami, Junichi (Hamamatsu University School of Medicine, Hamamatsu, Japan)
  
• Abstract:

  Background: Erlotinib is a selective inhibitor of the epidermal growth factor receptor tyrosine kinase. The relations between the concentrations of its active metabolites, OSI-413 and OSI-420, and clinical response or adverse effect remain unclear. In earlier methods, the concentrations of these metabolites were determined as a total amount.
  Aims: ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login